| Afshan A Ornan, MD | |
|
9101 Stony Point Dr, Richmond, VA 23235 | |
| (804) 330-9105 | |
| (804) 521-1061 |
| Full Name | Afshan A Ornan |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 19 Years |
| Location | 9101 Stony Point Dr, Richmond, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619176690 | NPI | - | NPPES |
| 1619176690 | Medicaid | VA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virginia Urology Center | 2365339264 | 82 |
News Archive
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
Children from low-income neighborhoods had a higher mortality rate and higher hospital costs after heart surgery compared with those from higher-income neighborhoods, found a national study of more than 86,000 kids with congenital heart disease.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.
A lethal concoction of racing fuel and Mountain Dew claimed the lives of two Tennessee teens and has sparked the Tennessee Poison Center to warn about the lethality of what has been called "Dewshine."
› Verified 6 days ago
| Entity Name | Virginia Urology Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164485876 PECOS PAC ID: 2365339264 Enrollment ID: O20040304000209 |
News Archive
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
Children from low-income neighborhoods had a higher mortality rate and higher hospital costs after heart surgery compared with those from higher-income neighborhoods, found a national study of more than 86,000 kids with congenital heart disease.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.
A lethal concoction of racing fuel and Mountain Dew claimed the lives of two Tennessee teens and has sparked the Tennessee Poison Center to warn about the lethality of what has been called "Dewshine."
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Afshan A Ornan, MD 9101 Stony Point Dr, Richmond, VA 23235 Ph: (804) 330-9105 | Afshan A Ornan, MD 9101 Stony Point Dr, Richmond, VA 23235 Ph: (804) 330-9105 |
News Archive
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
Children from low-income neighborhoods had a higher mortality rate and higher hospital costs after heart surgery compared with those from higher-income neighborhoods, found a national study of more than 86,000 kids with congenital heart disease.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.
A lethal concoction of racing fuel and Mountain Dew claimed the lives of two Tennessee teens and has sparked the Tennessee Poison Center to warn about the lethality of what has been called "Dewshine."
› Verified 6 days ago
Dr. Christine H Llewellyn, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1250 E Marshall Street, Radiology, Richmond, VA 23298 Phone: 804-828-8262 Fax: 804-828-6129 | |
Kathryn S. Jones, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1250 E Marshall St, Richmond, VA 23298 Phone: 804-628-3580 Fax: 804-628-3593 | |
Dr. Richard Westwood Fuller, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2602 Buford Rd, Richmond, VA 23235 Phone: 804-272-8806 | |
Michelle S. Kraut, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 7110 Forest Ave, Suite 100, Richmond, VA 23226 Phone: 804-673-4200 Fax: 804-673-6513 | |
Dr. Matthew L Cohen, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2602 Buford Rd, Richmond, VA 23235 Phone: 804-272-8806 | |
Dr. Roger Headly Tutton, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1839 Monument Ave, Richmond, VA 23220 Phone: 804-355-7788 | |
Ryan D Clayton, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1250 E Marshall St, Radiology, Richmond, VA 23298 Phone: 804-628-6831 Fax: 804-628-1132 |